News
Article
Author(s):
ICYMI, this week we had news about the National Rosacea Society's Seal of Acceptance Program, Dermavant's submitted sNDA for tapinarof cream 1% to treat AD, Galderma's accepted BLA for nemolizumab for the treatment of prurigo nodularis and AD, and more.
Click here to answer this week’s acne poll.
The Skin Cancer Foundation’s initiative, Destination Healthy Skin, travels to various cities throughout the country in an RV, wherein volunteer dermatologists provide on-the-street, free-of-cost skin screenings.
Keep up with the latest headlines in dermatology from the past week, including biotech's potential role in alleviating symptoms of skin disease, new sun safety guidelines in Australia, and more.
Alongside expert dermatologists, the NRS recently developed a Seal of Acceptance for skin care and cosmetic products clinically tested and evaluated for patients with rosacea.
A recent study revealed improvements in sensitivity but highlighted disparities in diagnostic accuracy, particularly among non-specialists and in darker skin tones.
Artax announced that safety and efficacy data is expected in the second half of the year.
In this week’s Pointers With Portela, the 208SkinDoc discusses the recent trend of tweens buying excessive skin care.
Tapinarof cream demonstrated highly statistically significant improvement in the primary end point of vIGA-AD treatment success over vehicle at week 8.
This week’s collection of the latest dermatologic studies covers the causal relationship between lipid-related metabolites and androgenic alopecia, contact allergens in self-tanning products, a retrospective cross-sectional analysis of vitiligo patients in Canada, and combining systemic anti-PD-1 treatment with adjuvant ablative fractional laser in a mouse model of cutaneous SCC.
The resubmission follows the Complete Response Letter Citius received from the US FDA in July of 2023.
The FDA has also granted nemolizumab Priority Review for prurigo nodularis.
Click here to answer our poll about the upcoming conference in Puerto Rico.
Researchers noted that this study's findings are consistent with prior epidemiologic data.
A case report examined an incidence of storiform collagenoma, also known as sclerotic fibroma, associated with Cowden syndrome in a patient. This occurrence is considered rare.
An analysis of popular self-tanners revealed that more than half of them contained at least 10 potential allergens, and some contained 20 or more.
Click here to answer our poll about the upcoming conference.
Among the many sessions to be held at the Winter Clinical Miami 2024 Conference in Miami Beach, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.
New data on the devices will be available at the 2024 American Academy of Dermatology Annual Meeting.
In this month’s Cosmetic Conundrums column, explore skin barrier assessments, skin moisturization tests, and how to measure skin firmness.
The test may help patients with melanoma safely avoid a sentinel lymph node biopsy.
In an interview with Dermatology Times, the executive director of Pediatric Dermatology Research Alliance (PeDRA) discusses the group's growth since 2012 and what it can offer practicing dermatologists, researchers, students, and patients.
We want to know your thoughts on the recent guidelines. Share with us by answering our poll or emailing us at DTEditor@mmhgroup.com.
Learn what makes the Masterclasses in Dermatology conference a unique educational opportunity, and take a quick poll to tell us what you want to learn.
The IFPA Forum Roadmap for Asia outlines key advocacy demands and practical strategies to improve psoriatic care throughout the continent.
The combination therapy did not yield any effect in patients with non-segmental vitiligo and prompts additional large studies prior to conclusive efficacy.
An investigation into skin changes at the cellular level provides insight into hyaluronic acid’s benefits.
Dive into a complex case report of a 29-year-old African American male patient with Fitzpatrick skin type V with a 6-month reported history of vitiligo on his lips.
Japan is the first country in the world to approve dupilumab for the treatment of chronic spontaneous urticaria (CSU).
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.